GlassScriptPhysician profile
Evan M Johnson
NPI 1659399772
$2,558.98
in general payments reported to CMS, 2019-2025
25 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $162 · 2021: $1,467 · 2022: $95.79 · 2023: $78.45 · 2024: $162 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,162.76 | 2021 | |
| Amgen INC. | $171.21 | 2019-2025 | Repatha, Otezla, Evenity |
| Kowa Pharmaceuticals America, INC. | $130.83 | 2019-2022 | |
| Novo Nordisk INC | $122.67 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $114.39 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $110.62 | 2019-2023 | Farxiga |
| Depuy Synthes Sales INC. | $110.29 | 2021 | |
| Glaxosmithkline, LLC. | $106.81 | 2023-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $87.54 | 2019-2022 | |
| Abbvie INC. | $52.70 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $43.54 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $43.20 | 2019-2020 | |
| Dexcom, INC. | $42.53 | 2021-2025 | Dexcom G6 Transmitter |
| Melinta Therapeutics, LLC | $38.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.80 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.74 | 2024-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $27.51 | 2024 | Xyosted |
| Lilly USA, LLC | $21.52 | 2024 | Mounjaro |
| Gilead Sciences, INC. | $18.00 | 2025 | |
| Abbott Laboratories | $16.13 | 2021 | |
| Axsome Therapeutics, INC. | $13.54 | 2024 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $13.33 | 2024 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2019 | |
| Biogen, INC. | $11.54 | 2021 | |
| Allergan, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.